Key Highlights

  • Shares trading down 1.28% to $2.32 in today's session.
  • Trading Volume reached 21.95 thousand shares.
  • The company reported an EPS of negative $8.99.
  • Revised enrollment criteria have been approved at nine of eleven active trial sites.

Enrollment Criteria Widened to Speed Up Trial

Aclarion, Inc. (NASDAQ:ACON), a healthcare technology company focused on diagnosing chronic low back pain, said it broadened the enrollment criteria for its pivotal CLARITY trial after enrollment lagged under the original, more narrowly defined criteria. The revised criteria have now been approved at nine of the company's eleven active trial sites, with two more using them for screening ahead of local approval.

Timeline Update Expected by Year-End

The company said it will provide an update on enrollment levels and the anticipated timeline for its initial trial readout by year-end. Despite the changes, the company maintained that the overall length of the trial is not expected to be extended as a result of the adjustment.

Shares Dip Slightly Following the Update

Shares slipped modestly today, with an EPS of negative $8.99 reflecting the company's pre-commercial stage as it continues to generate evidence for its Nociscan diagnostic platform. The stock's 52-week range of $1.95 to $12.03 reflects its Volatility as a small, thinly traded name.

Outlook: Faster Enrollment Could Support Trial Timeline

With broader criteria now in place across most sites, the company expects meaningful acceleration in patient enrollment going forward. The upcoming year-end update may give investors clearer visibility into when the trial's initial data readout could arrive.